
    
      In this phase II trial, the investigators evaluate the efficacy and safety of S-588410
      containing oncoantigens-derived HLA-A*2402-restricted epitope peptides in patients with
      HLA-A*2402 who underwent an adjuvant chemotherapy after the complete resection of
      non-small-cell lung cancer.
    
  